bioMerieux (OTCMKTS:BMXMF) Hits New 1-Year High - Here's What Happened

Key Points

• bioMerieux's stock price reached a new 52-week high of $152.00 during trading, up from a previous close of $145.64, with a total trading volume of 100 shares.
• The Royal Bank of Canada downgraded bioMerieux from a "moderate buy" rating to a "hold" rating on May 7th, suggesting a shift in market sentiment.
• The company specializes in in vitro diagnostic solutions for infectious diseases, serving various regions, including the Americas, Europe, and Asia Pacific.

bioMerieux (OTCMKTS:BMXMF - Get Free Report)'s share price hit a new 52-week high on Monday . The stock traded as high as $152.00 and last traded at $152.00, with a volume of 100 shares trading hands. The stock had previously closed at $145.64.

Analysts Set New Price Targets

Separately, Royal Bank Of Canada lowered bioMerieux from a "moderate buy" rating to a "hold" rating in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock presently has an average rating of "Hold".

bioMerieux Price Performance

The company has a quick ratio of 1.29, a current ratio of 2.20 and a debt-to-equity ratio of 0.08. The company has a fifty day moving average price of $143.61 and a two-hundred day moving average price of $132.70.

bioMerieux Company Profile

bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.